FTH — Faeth Therapeutics Share News
0.000.00%
Last trade - 00:00- $519.39m
- $332.95m
U.S. RESEARCH ROUNDUP-Abbvie, Lionsgate Studios, UnitedHealth Group
Brief: Sensei Biotherapeutics Reports Encouraging Clinical Data From Dose Escalation Portion Of Its Phase 1/2 Trial Of SNS-101
Sensei Biotherapeutics Inc reports results for the quarter ended in March - Earnings Summary
Sensei Biotherapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview
Brief: Erin Colgan Notified Sensei Biotherapeutics Of Her Resignation From All Positions With Co, Including As CFO, On March 27
Brief: Sensei Biotherapeutics Says Board Approved A Reduction In Number Of Directors On Board From Nine To Eight On Feb 6
Brief: Sensei Biotherapeutics Provides Corporate Update And Upcoming Milestones
Brief: Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
U.S. STOCKS ON THE MOVE-Paramount Global, Bumble, Booking Holdings
U.S. STOCKS ON THE MOVE-Constellation Energy, Bloomin' Brands, Air Lease
U.S. STOCKS ON THE MOVE-Sensei, Celldex, Bluegreen Vacations
Sensei up after receiving and declining Newtyn's buyout proposal
Sensei Biotherapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Sensei Biotherapeutics Presents Trial-In-Progress Poster For Phase 1/2 Clinical Study Of Sns-101 At Esmo 2023
Sensei Biotherapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Sensei Biotherapeutics posts Q2 basic EPS USD -0.31
Brief: Sensei Biotherapeutics Announces First Patient Dosed In Phase 1/2 Clinical Trial Of Sns-101, A Conditionally Active Vista-Blocking Antibody, For The Treatment Of Advanced Solid Tumors
Brief: Sensei Biotherapeutics Inc - Entered Into A Purchase Agreement With Apeiron Investment Group Ltd And Others
Brief: Sensei Biotherapeutics Reports Q1 2023 Financial Results And Recent Business Highlights